Detail akcie Avidity Biosci Rg online

Business Summary: Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Avidity Biosciences Inc revenues increased from $7.9M to $17.9M. Net loss increased from $220M to $447.5M. Revenues reflect Pharmaceutical segment increase from $7.9M to $16.3M, United States segment increase from $7.9M to $16.3M. Higher net loss reflects Pharmaceutical segment loss increase of 40% to $359.9M, United States segment loss increase of 40% to $359.9M.